Canadian Solar (CSIQ) Supplies Conti/SunDurance with 11-MW of Modules in Q2 Sep 2, 2014 07:40AM

Canadian Solar (Nasdaq: CSIQ) announced that it supplied Conti / SunDurance with 11 MW of solar modules during the second quarter of 2014.

For this 11MW order, Canadian Solar delivered to the Conti Group in total 37,202 pieces of CS6X solar modules in 6 x 12 cell matrix with UL 1000V certificate. During their 25 year life span, these modules will turn solar energy into 360,000 MWh of electricity, and reduce CO2 emissions by 67,000 tons, the equivalent to taking 11,800 cars off of the roads; or equivalent to creating a forest of 6,200 hectares with 237,000 trees.

As a leading provider of engineering, procurement and construction (EPC) services in the renewable energy and other industrial markets internationally, the Conti Group has installed over 70 MW of solar projects throughout the United States. Matthew Skidmore, Vice President at Conti, commented, "We partner with sophisticated solar developers, solar asset owners and electrical utilities to design and build large scale projects, and are very excited to work with Canadian Solar on this opportunity."

"We are pleased to be selected to supply our PV modules to Conti, a world leading EPC provider. We are looking forward to working with Conti in the future. I am confident that Canadian Solar's global leadership, proven track record, and well-known brand name will continue to make us a partner of choice in powering key solar installations worldwide," said Dr. Shawn Qu, Chairman and Chief Executive Officer of Canadian Solar.

In the past few years, Canadian Solar modules have consistently been ranked at the top of the PTC Ratings in the industry. PTC Ratings, established by the California Energy Commission (CEC), is the widely accepted indicator of real-world PV module performance.


Zogenix (ZGNX) Issues Positive Update on Post-Hoc Analysis of Zohydro ER Sep 2, 2014 07:31AM

Zogenix (Nasdaq: ZGNX) announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro ER, (hydrocodone bitartrate) Extended-Release Capsules, CII, provided durable pain relief over the entire dosing interval. This finding is important because a major concern for all extended-release pain medications is the potential for lack of consistent pain relief throughout the entire day, especially at the end of the dosing.

"In this study, we saw that most of the chronic pain patients taking Zohydro ER achieved effective pain relief for the entire duration of 12 hours for each administered dose. In particular, most patients did not experience dose failures during the night, meaning they did not wake up to take additional medication for their pain," said Srinivas Nalamachu, MD, President and Medical Director, International Clinical Research Institute, Overland Park, Kansas.

The goal of extended-release opioids is to provide sustained delivery of medication and continuous pain relief over the entire dosing interval, reducing or eliminating the need to take rescue pain medication. Chronic pain patients experiencing interruptions in sleep frequently have higher degrees of pain and reduced functioning the following day. 1

These data will be presented at PAINWeek, the national conference on pain for clinicians specializing in pain management taking place this week in Las Vegas.

"Zohydro ER was developed specifically for the subset of severe chronic pain patients currently managing their pain with short-acting hydrocodone/acetaminophen medication but who need true sustained 12-hour pain relief and are at risk for acetaminophen toxicity. These data further support that Zohydro ER fulfills this medical need," said Bradley Galer, MD, chief medical officer of Zogenix. "This analysis of our pivotal Phase 3 data demonstrated that pain relief with Zohydro ER was durable throughout the entire 12-hour dosing interval without any observation of end of dose failure. This finding, coupled with the lack of the need to wake up at night to take rescue pain medication, is particularly important, since minimizing the amount of rescue medication and providing around-the-clock pain relief are often overlooked factors in the effective treatment of severe chronic pain."

Zohydro® ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Zohydro ER is the first and only extended-release hydrocodone for around-the clock management of severe chronic pain without acetaminophen, lowering the risk for liver toxicity due to overexposure of acetaminophen, which can be fatal or require a liver transplant.


Amphenol (APH) to Acquire CASCO in $450M Deal Sep 2, 2014 07:27AM

Amphenol (NYSE: APH) has entered into a definitive agreement to acquire the Casco Automotive Group (CASCO), a division of Cap-Con Automotive Technologies Ltd. (Cap-Con) for approximately $450 million (subject to customary closing adjustments). Cap-Con is owned by a private investment fund managed by The Jordan Company II, L.P. and Cap-Con management. The sale is subject to certain regulatory approvals and other customary closing conditions and is expected to close prior to year end.

Casco, headquartered in Bridgeport, Connecticut, is a supplier of highly engineered data connectivity, power, charging and sensor products to the worldwide automotive market, with annual sales of approximately $220 million. Casco has facilities in the Americas, Europe and Asia and employs approximately 1,300 people worldwide.

“We are extremely pleased to announce this agreement to add Casco to the Amphenol family,” said R. Adam Norwitt, Amphenol’s President and CEO. “We believe that Casco’s product offerings are uniquely complementary to our existing offering and represent a significant long-term expansion opportunity driven by the expansion of electronics across a broad set of applications in the automotive market. We look forward to working in partnership with Casco’s experienced management team to deliver additional high technology solutions to our customers.”

“Consistent with our acquisition strategy and assuming a continuation of current economic conditions, we expect the Casco acquisition to be accretive to earnings per share in the first year post acquisition.”

Amphenol will provide further information regarding the acquisition at its regularly scheduled quarterly earnings call to discuss Third Quarter earnings scheduled for October 22, 2014.


Salix Pharma (SLXP) Issues Response to CRL on XIFAXAN 550mg sNDA Sep 2, 2014 07:20AM

Salix Pharma (NASDAQ: SLXP) announced that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company’s supplemental New Drug Application (sNDA) for XIFAXAN® 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix’s response, the FDA will have six months to issue a response.

“We are pleased that the outcome of TARGET 3 provides both prospective controlled data to support the efficacy and safety of repeat treatment with rifaximin,” stated Bill Forbes, PharmD, Executive Vice President, Medical, Research and Development and Chief Development Officer, Salix. “Beyond corroborating the efficacy and safety results of TARGET 1 and TARGET 2, the results of TARGET 3 provide important microbiome as well as culture and susceptibility results that provide additional support of the safety of repeat treatment with rifaximin. These compelling data should provide adequate information for the basis of the product labeling used to guide patients and their health care providers on how to safely and most effectively administer repeat treatment of rifaximin in patients with recurrence in their symptoms of IBS-D. We look forward to continuing our collaborative discussion with the FDA with our response in this submission.”

During its original review of Salix’s sNDA, the FDA determined it is important in a chronic condition such as IBS to have information about how a product that is intended for short course administration in order to confer prolonged benefit should be administered beyond the first cycle of use once symptoms reappear. In addition, the FDA determined that patients and their health care providers should have information on the safety and effectiveness of this retreatment. The FDA conveyed this information to Salix in a March 7, 2011, CRL. Over the past three and one-half years, Salix and the FDA worked collaboratively to develop a study protocol (TARGET 3) intended to collect prospective controlled data to support repeat treatment with rifaximin in order to obtain adequate information for product labeling to guide patients and their health care providers on how to safely and most effectively administer repeat treatment of rifaximin in patients with IBS. This collaboration with the FDA also included a publicly held meeting with the Gastrointestinal Drugs Advisory Committee on November 16, 2011.


ReneSola (SOL) Announces 13-MW Solar Farm Project in England; Already Identified Potential Buyers Sep 2, 2014 07:18AM

ReneSola (NYSE: SOL) announced that it will develop a 13MW solar project in Dorset, England. The Company expects the solar farm to be fully operational and connected to the national energy grid by end of this year.

The Company has identified a number of potential buyers for the project, which received planning consent in January 2014 and is eligible for the United Kingdom's support scheme to promote renewable electricity-generating technologies. The project will feature ReneSola PV modules exclusively, specifically the Company's top-rated Virtus II."While we remain focused on our retail and residential-oriented business development, we selectively pursue project opportunities across our key markets when we identify good value and when the projects are in line with our broader strategic objectives," said Mr. Xianshou Li, ReneSola's chief executive officer. "The United Kingdom is one of our best-performing markets, and one of the world's fastest-growing major solar markets, while the new project will further strengthen our leading market position in UK. The 13MW Dorset project will be one of a series of selective projects we plan to build in the coming quarters."


More Corporate News

View Older Stories

Sep 2, 2014 07:17AM Himax Technologies (HIMX), Optinvent SA Expand Relationship to Develop Next-Gen Augmented Reality Glasses
Sep 2, 2014 07:16AM China HGS Real Estate (HGSH) Reports $750M Shanty Area Rebuilding Project Agreement
Sep 2, 2014 07:14AM Alder BioPharmaceuticals (ALDR) Regains Clazakizumab Rights from Bristol-Myers (BMY)
Sep 2, 2014 07:11AM Cepheid (CPHD) Announces Release of Xpert Flu/RSV XC in Europe
Sep 2, 2014 07:09AM Cardtronics (CATM) Enters ATM Operating Agreement with Co-op Food; Will Acquire SSG in GBP41.5M Deal
Sep 2, 2014 07:07AM Callon Petroleum (CPE) to Expand Presence in Texas with $213M Property Grab
Sep 2, 2014 07:04AM BioCryst Pharma (BCRX) to Present Peramivir IV Data at ICAAC
Sep 2, 2014 06:47AM Microchip Technology (MCHP): Any Offer for CSR plc (CSRE) Likely to Be in Cash
Sep 2, 2014 06:38AM RCS Capital (RCAP) Completes SCA Acquisition
Sep 2, 2014 06:35AM Regeneron (REGN), Sanofi (SNY) Update on Four Alirocumab Phase 3s
Sep 2, 2014 06:23AM Invacare Corp. (IVC) Completes $23M Sale of Altimate Medical
Sep 2, 2014 06:20AM Exelixis, Inc. (EXEL) COMET-1 Phase 3 Trial Fails to Meet Primary Endpoint
Sep 2, 2014 05:54AM St. Jude Medical (STJ) Issues Positive Update on FFR in NSTEMI
Aug 29, 2014 04:38PM Hercules Technology Growth Capital (HTGC) COO Resigns
Aug 29, 2014 04:20PM BE Aerospace (BEAV) Reports Filing of Registration Statement for Spin-off
Aug 29, 2014 04:06PM Mast Therapeutics (MSTX) CMO to Depart, Replacement Named
Aug 29, 2014 04:01PM Donegal Group, Inc. (DGICA) Reports CEO on Medical Leave
Aug 29, 2014 03:59PM American Airlines Group (AAL)/Orbitz Worldwide (OWW) Reach Agreement; American Airlines Back on Orbitz Sites
Aug 29, 2014 02:33PM Ormat Technologies (ORA) Signs $140M Loan to Finance Construction at McGinness Hills
Aug 29, 2014 02:25PM Vicon Industries (VII) Completes IQinVision Merger; Sets Special Dividend Payment Date
Aug 29, 2014 02:21PM Authentidate Holding (ADAT) Corrects Error; Sees Gross Proceeds of $2.17M from Upcoming Direct Placement
Aug 29, 2014 02:19PM European Commission Approves Oracle's (ORCL) Acquisition of MICROS (MCRS)
Aug 29, 2014 01:02PM Kraft Foods Group (KRFT) Recalls Select Varieties of Kraft American Singles
Aug 29, 2014 12:53PM United Therapeutics (UTHR) Confirms Favorable Ruling in Remodulin Patent Case
Aug 29, 2014 12:23PM Vaalco Energy (EGY) Reports Resumption of Etame Marin Block Operations Offshore Gabon
Aug 29, 2014 11:51AM Bancfirst Corp (BANF) Does Not Know Reason for Unusual Trading Activity in Preferred Securities
Aug 29, 2014 11:31AM Las Vegas Sands (LVS) Announces Completion of Amended, Restated Marina Bay Sands Credit Facility
Aug 29, 2014 11:09AM Arena Pharma (ARNA) Gets Orphan Status for PAH Treatment
Aug 29, 2014 10:56AM United Therapeutics (UTHR) Gains After Judge Rules Remodulin Patents are Not Invalid
Aug 29, 2014 10:56AM United Therapeutics (UTHR) Gains After Judge Rules Remodulin Patents are Not Invalid
Aug 29, 2014 10:11AM Sanofi (SNY) Fabry Disease Treatment Receives FDA Orphan Designation
Aug 29, 2014 09:38AM Kandi Technologies Group (KNDI) Enters $71M Common Direct Placement
Aug 29, 2014 09:08AM NASCO Products (XXII), Smoker Friendly Enter Manufacturing Agreement
Aug 29, 2014 08:20AM ViewPoint Financial Group (VPFG), LegacyTexas Amend Merger Agreement
Aug 29, 2014 07:17AM Rubicon Mineral (RBY) Reports Dismissal of Phoenix Gold Project Review
Aug 29, 2014 07:10AM BioCryst Pharma (BCRX) Receives $2.4M Contract Modification from NIAID for BCX4430 Efficacy Study
Aug 29, 2014 06:41AM Glori Energy (GLRI) Meets Requirements for Nasdaq CM Listing
Aug 29, 2014 06:39AM Albemarle (ALB), ICL Enters Agreements for Polymeric Development
Aug 29, 2014 06:28AM China Unicom (CHU) Approved to Conduct TD-LTE/LTE FDD Hybrid Tests
Aug 29, 2014 06:03AM The9 Limited (NCTY) Enters Five-Year Publishing Agreement for Firefall in China
Aug 29, 2014 06:02AM The9 Limited (NCTY) Closes Transaction with Shanghai Zhengwu
Aug 28, 2014 05:45PM Microchip Technology, Inc. (MCHP) Confirms Talks with CSR (CSRE) About Possible Acquisition
Aug 28, 2014 05:27PM ERA Group (ERA) CEO Resigns; Replacement Named
Aug 28, 2014 04:38PM CCA Industries (CAW) Unloads Mega-T Brand Weight Loss Business
Aug 28, 2014 04:35PM Papa Murphy's (FRSH) Closes $132M Facility
Aug 28, 2014 04:32PM Tyson Foods (TSN) and Hillshire Brands (HSH) Complete Merger
Aug 28, 2014 04:29PM Alpha Natura (ANR) Unit Receives Imminent Danger Order from MSHA; No Citations Issued
Aug 28, 2014 02:43PM UPDATE: Repsol Drops Plans to Buy all of Talisman Energy (TLM) - Bloomberg
Aug 28, 2014 01:42PM Forward Industries' (FORD) Largest Shareholder Calls Dismissal of CFO 'Reckless'
Aug 28, 2014 01:37PM Xerox Corp. (XRX) Staff Won't Be Charged by SEC Related to ACS Accounting Practices
View Older Stories